Checkpoint Therapeutics(CKPT) - 2024 Q1 - Quarterly Results

Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates · Checkpoint submitted a BLA to the FDA in January 2023 seeking approval of cosibelimab as a potential new treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma ("cSCC") who are not candidates for curative surgery or curative radiation, and the FDA accepted the BLA for filing in March 2023. In December 2023, the FDA issued a CRL for the cosibelimab BLA. The CRL only cited ...